Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Review Article
  • Published:

Novel perspectives in the management of decompensated cirrhosis

Nature Reviews Gastroenterology & Hepatology volume 15, pages 753–764 (2018)Cite this article

Subjects

Abstract

The current approaches to the management of patients with decompensated cirrhosis are based on targeted strategies aimed at preventing or treating specific complications of the disease. The improved knowledge of the pathophysiological background of advanced cirrhosis, represented by a sustained systemic inflammation strictly linked to a circulatory dysfunction, provides a novel paradigm for the management of these patients, with the ambitious target of modifying the course of the disease by preventing the onset of complications and multiorgan failure; these interventions will eventually improve patients’ quality of life, prolong survival and reduce health-care costs. Besides aetiological treatments, these goals could be achieved by persistently antagonizing key pathophysiological events, such as portal hypertension, abnormal bacterial translocation from the gut, liver damage, systemic inflammation, circulatory dysfunction and altered immunological responses. Interestingly, in addition to strategies based on new therapeutic agents, these targets can be tackled by employing drugs that are already used in patients with cirrhosis for different indications or in other clinical settings, including non-absorbable oral antibiotics, non-selective β-blockers, human albumin and statins. The scope of the present Review includes reporting updated information on the treatments that promise to influence the course of advanced cirrhosis and thus act as disease-modifying agents.

Key points

  • The management of decompensated cirrhosis currently addresses the prevention or treatment of specific complications; disease-modifying agents able to modify the course of decompensated cirrhosis still represent an unmet need.

  • Removing aetiological factors can halt the progression of chronic liver disease, yet a substantial portion of patients with decompensated cirrhosis do not benefit from even successful aetiological treatments.

  • Portal hypertension, abnormal translocation of bacterial products from the gut (‘upstream’ events) and the consequent systemic inflammation and circulatory dysfunction (‘downstream’ events) represent the main targets for mechanistic approaches.

  • Transjugular portosystemic shunt and non-selective β-blockers can be seen as upstream treatments, as they lower portal hypertension and might prevent bacterial translocation.

  • Bacterial translocation can be antagonized by antibiotic-based and non-antibiotic-based interventions, but the former entail the risk of antibiotic resistance, whereas the efficacy of the latter still needs to be demonstrated.

  • Human albumin and statins, which are able to simultaneously target several downstream pathophysiological mechanisms, represent promising disease-modifying agents, as they have proved their efficacy in prospective randomized trials.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Fig. 1: Pathophysiological background of clinical manifestations in decompensated cirrhosis.
Fig. 2: Potential pathophysiological treatments in decompensated cirrhosis.
Fig. 3: Pleiotropic effects of statins.
Fig. 4: Functional properties of human albumin and potential target mechanisms in decompensated cirrhosis.

Similar content being viewed by others

References

  1. D’Amico, G., Garcia-Tsao, G. & Pagliaro, L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J. Hepatol. 44, 217–231 (2006).

    PubMed  Google Scholar 

  2. Ginés, P., Fernández, J., Durand, F. & Saliba, F. Management of critically-ill cirrhotic patients. J. Hepatol. 56 (Suppl. 1), S13–S24 (2012).

    PubMed  Google Scholar 

  3. Moreau, R. et al. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology 144, 1426–1437 (2013).

    PubMed  Google Scholar 

  4. Albillos, A., Lario, M. & Alvarez-Mon, M. Cirrhosis-associated immune dysfunction: distinct features and clinical relevance. J. Hepatol. 61, 1385–1396 (2014).

    PubMed  CAS  Google Scholar 

  5. Schrier, R. W. et al. Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis. Hepatology 8, 1151–1157 (1988).

    PubMed  CAS  Google Scholar 

  6. García-Pagán, J. C., Gracia-Sancho, J. & Bosch, J. Functional aspects on the pathophysiology of portal hypertension in cirrhosis. J. Hepatol. 57, 458–461 (2012).

    PubMed  Google Scholar 

  7. Wiese, S., Hove, J. D., Bendtsen, F. & Møller, S. Cirrhotic cardiomyopathy: pathogenesis and clinical relevance. Nat. Rev. Gastroenterol. Hepatol. 11, 177–186 (2014).

    PubMed  CAS  Google Scholar 

  8. Arroyo, V., Terra, C. & Ginés, P. Advances in the pathogenesis and treatment of type-1 and type-2 hepatorenal syndrome. J. Hepatol. 46, 935–946 (2007).

    PubMed  CAS  Google Scholar 

  9. Iwakiri, Y. & Groszmannm, R. J. The hyperdynamic circulation of chronic liver diseases: from the patient to the molecule. Hepatology 43 (2 Suppl. 1), S121–S131 (2006).

    PubMed  CAS  Google Scholar 

  10. Bernardi, M., Moreau, R., Angeli, P., Schnabl, B. & Arroyo, V. Mechanisms of decompensation and organ failure in cirrhosis: from peripheral arterial vasodilation to systemic inflammation hypothesis. J. Hepatol. 63, 1272–1284 (2015).

    PubMed  CAS  Google Scholar 

  11. Wiest, R., Lawson, M. & Geuking, M. Pathological bacterial translocation in liver cirrhosis. J. Hepatol. 60, 197–209 (2014).

    PubMed  Google Scholar 

  12. Sriskandan, S. & Altmann, D. M. The immunology of sepsis. J. Pathol. 214, 211–223 (2008).

    PubMed  CAS  Google Scholar 

  13. Kawai, T. & Akira, S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol. 11, 373–384 (2010).

    PubMed  CAS  Google Scholar 

  14. Hotchkiss, R. S. et al. Sepsis and septic shock. Nat. Rev. Dis. Primers. 2, 16045 (2016).

    PubMed  PubMed Central  Google Scholar 

  15. Clària, J. et al. Systemic inflammation in decompensated cirrhosis: characterization and role in acute-on-chronic liver failure. Hepatology 64, 1249–1264 (2016).

    PubMed  Google Scholar 

  16. European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J. Hepatol. https://doi.org/10.1016/j.jhep.2018.03.024 (2018).

    Article  Google Scholar 

  17. O’Brien, J., Triantos, C. & Burroughs, A. K. Management of varices in patients with cirrhosis. Nat. Rev. Gastroenterol. Hepatol. 10, 402–412 (2013).

    PubMed  Google Scholar 

  18. Fagiuoli, S. et al. Consensus conference on TIPS management: techniques, indications, contraindications. Dig. Liver Dis. 49, 121–137 (2017).

    PubMed  Google Scholar 

  19. Prakash, R. & Mullen, K. D. Mechanisms, diagnosis and management of hepatic encephalopathy. Nat. Rev. Gastroenterol. Hepatol. 7, 515–525 (2010).

    PubMed  Google Scholar 

  20. Fernández, J., Tandon, P., Mensa, J. & Garcia-Tsao, G. Antibiotic prophylaxis in cirrhosis: good and bad. Hepatology 63, 2019–2031 (2016).

    PubMed  Google Scholar 

  21. Böttcher, K. & Pinzani, M. Pathophysiology of liver fibrosis and the methodological barriers to the development of anti-fibrogenic agents. Adv. Drug. Deliv. Rev. 121, 3–8 (2017).

    PubMed  Google Scholar 

  22. Marcellin, P. et al. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 381, 468–475 (2013).

    PubMed  CAS  Google Scholar 

  23. Di Marco, V. et al. Effects of eradicating hepatitis C virus infection in patients with cirrhosis differ with stage of portal hypertension. Gastroenterology 151, 130–139 (2016).

    PubMed  Google Scholar 

  24. Nahon, P. et al. Eradication of hepatitis C virus infection in patients with cirrhosis reduces risk of liver and non-liver complications. Gastroenterology 152, 142–156 (2017).

    PubMed  Google Scholar 

  25. Takahashi, H., Shigefuku, R., Maeyama, S. & Suzuki, M. Cirrhosis improvement to alcoholic liver fibrosis after passive abstinence. BMJ Case Rep. 2014, bcr2013201618 (2014).

    PubMed  PubMed Central  Google Scholar 

  26. Lok, A. S. et al. Antiviral therapy for chronic hepatitis B viral infection in adults: a systematic review and meta-analysis. Hepatology 63, 284–306 (2016).

    PubMed  CAS  Google Scholar 

  27. Curry, M. P. et al. Sofosbuvir and Velpatasvir for HCV in patients with decompensated cirrhosis. N. Engl. J. Med. 373, 2618–2628 (2015).

    PubMed  CAS  Google Scholar 

  28. Foster, G. R. et al. Impact of direct acting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. 64, 1224–1231 (2016).

    PubMed  CAS  Google Scholar 

  29. Cheung, M. C. et al. Outcomes after successful direct-acting antiviral therapy for patients with chronic hepatitis C and decompensated cirrhosis. J. Hepatol. 65, 741–747 (2016).

    PubMed  CAS  Google Scholar 

  30. Martini, S. et al. The Italian compassionate use of sofosbuvir in HCV patients waitlisted for liver transplantation: a national real-life experience. Liver Int. 38, 733–741 (2017).

    PubMed  Google Scholar 

  31. Veldt, B. J. et al. Indication of liver transplantation in severe alcoholic liver cirrhosis: quantitative evaluation and optimal timing. J. Hepatol. 36, 93–98 (2002).

    PubMed  Google Scholar 

  32. Carrillo, C. F. et al. Treatment of hepatitis C virus infection in patients with cirrhosis and predictive value of model for end-stage liver disease: analysis of data from the Hepa-C Registry. Hepatology 65, 1810–1822 (2017).

    Google Scholar 

  33. Pascasio, J. M. et al. Clinical outcomes of patients undergoing antiviral therapy while awaiting liver transplantation. J. Hepatol. 67, 1168–1176 (2017).

    PubMed  Google Scholar 

  34. Shim, J. H. et al. Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J. Hepatol. 52, 176–182 (2010).

    PubMed  CAS  Google Scholar 

  35. Alvarez, M. A. et al. Long-term clinical course of decompensated alcoholic cirrhosis. A prospective study of 165 patients. J. Clin. Gastroenterol. 45, 906–911 (2011).

    PubMed  Google Scholar 

  36. Trebicka, J. et al. Endotoxin and tumor necrosis factor-receptor levels in portal and hepatic vein of patients with alcoholic liver cirrhosis receiving elective transjugular intrahepatic portosystemic shunt. Eur. J. Gastroenterol. Hepatol. 23, 1218–1225 (2011).

    PubMed  CAS  Google Scholar 

  37. Trebicka, J. Emergency TIPS in a Child-Pugh B patient: when does the window of opportunity open and close? J. Hepatol. 66, 442–450 (2017).

    PubMed  Google Scholar 

  38. Berres, M. L. et al. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt insertion. J. Hepatol. 62, 332–339 (2015).

    PubMed  CAS  Google Scholar 

  39. Halabi, S. A. et al. Early TIPS versus endoscopic therapy for secondary prophylaxis after management of acute esophageal variceal bleeding in cirrhotic patients: a meta-analysis of randomized controlled trials. J. Gastroenterol. Hepatol. 31, 1519–1526 (2016).

    PubMed  Google Scholar 

  40. Salerno, F., Cammà, C., Enea, M., Rössle, M. & Wong, F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology 133, 825–834 (2007).

    PubMed  CAS  Google Scholar 

  41. Chen, R. P. et al. Prophylactic use of transjugular intrahepatic portosystemic shunt aids in the treatment of refractory ascites: metaregression and trial sequential meta-analysis. J. Clin. Gastroenterol. 48, 290–299 (2014).

    PubMed  Google Scholar 

  42. Bureau, C. et al. Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites. Gastroenterology 152, 157–163 (2017).

    PubMed  Google Scholar 

  43. De Franchis, R. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: stratifying risk and individualizing care for portal hypertension. J. Hepatol. 63, 743–752 (2015).

    PubMed  Google Scholar 

  44. Ohnishi, K. et al. Effects of propranolol on portal hemodynamics in patients with chronic liver disease. Am. J. Gastroenterol. 80, 132–135 (1985).

    PubMed  CAS  Google Scholar 

  45. Bosch, J. Carvedilol for portal hypertension in patients with cirrhosis. Hepatology 51, 2214–2218 (2010).

    PubMed  CAS  Google Scholar 

  46. Straub, R. H., Wiest, R., Strauch, U. G., Härle, P. & Schölmerich, J. The role of the sympathetic nervous system in intestinal inflammation. Gut 55, 1640–1649 (2006).

    PubMed  PubMed Central  CAS  Google Scholar 

  47. Madsen, B. S., Havelund, T. & Krag, A. Targeting the gut-liver axis in cirrhosis: antibiotics and non-selective β-blockers. Adv. Ther. 30, 659–670 (2013).

    PubMed  CAS  Google Scholar 

  48. Perez-Paramo, M. et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 31, 43–48 (2000).

    PubMed  CAS  Google Scholar 

  49. Worlicek, M. et al. Splanchnic sympathectomy prevents translocation and spreading of E coli but not S aureus in liver cirrhosis. Gut 59, 1127–1134 (2010).

    PubMed  CAS  Google Scholar 

  50. Reiberger, T. et al. Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. J. Hepatol. 58, 911–921 (2013).

    PubMed  CAS  Google Scholar 

  51. Senzolo, M. et al. Beta-blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 29, 1189–1193 (2009).

    PubMed  CAS  Google Scholar 

  52. Merli, M. et al. The chronic use of beta-blockers and proton pump inhibitors may affect the rate of bacterial infections in cirrhosis. Liver Int. 35, 362–369 (2015).

    PubMed  Google Scholar 

  53. Sersté, T. et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology 52, 1017–1022 (2010).

    PubMed  Google Scholar 

  54. Mandorfer, M. et al. Nonselective beta blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology 146, 1680–1690 (2014).

    PubMed  CAS  Google Scholar 

  55. Mookerjee, R. P. et al. Treatment with non-selective beta blockers is associated with reduced severity of systemic inflammation and improved survival of patients with acute-on-chronic liver failure. J. Hepatol. 64, 574–582 (2016).

    PubMed  CAS  Google Scholar 

  56. Shah, N. et al. Prevention of acute kidney injury in a rodent model of cirrhosis following selective gut decontamination is associated with reduced renal TLR4 expression. J. Hepatol. 56, 1047–1053 (2012).

    PubMed  CAS  Google Scholar 

  57. Kainth, S. et al. Efficacy and safety of Carvedilol in patients of acute-on-chronic liver failure with small or no esophageal varices. A placebo control open label randomised trial. Hepatology 66 (Suppl. 1), 83A (2017).

    Google Scholar 

  58. Jalan, R. et al. Bacterial infections in cirrhosis: a position statement based on the EASL Special Conference 2013. J. Hepatol. 60, 1310–1324 (2014).

    PubMed  Google Scholar 

  59. Runyon, B. A. et al. Effect of selective bowel decontamination with norfloxacin on spontaneous bacterial peritonitis, translocation, and survival in an animal model of cirrhosis. Hepatology 21, 1719–1724 (1995).

    PubMed  CAS  Google Scholar 

  60. Llovet, J. M. et al. Selective intestinal decontamination with norfloxacin reduces bacterial translocation in ascitic cirrhotic rats exposed to hemorrhagic shock. Hepatology 23, 781–787 (1996).

    PubMed  CAS  Google Scholar 

  61. Albillos, A. et al. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology 37, 208–217 (2003).

    PubMed  CAS  Google Scholar 

  62. Soriano, G. et al. Norfloxacin prevents bacterial infection in cirrhotics with gastrointestinal hemorrhage. Gastroenterology 103, 1267–1272 (1992).

    PubMed  CAS  Google Scholar 

  63. Bernard, B. et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with ascites: a meta-analysis. Digestion 59 (Suppl. 2), 54–57 (1998).

    PubMed  Google Scholar 

  64. Loomba, R., Wesley, R., Bain, A., Csako, G. & Pucino, F. Role of fluoroquinolones in the primary prophylaxis of spontaneous bacterial peritonitis: meta-analysis. Clin. Gastroenterol. Hepatol. 7, 487–493 (2009).

    PubMed  Google Scholar 

  65. Fernández, J. et al. Primary prophylaxis of spontaneous bacterial peritonitis delays hepatorenal syndrome and improves survival in cirrhosis. Gastroenterology 133, 818–824 (2007).

    PubMed  Google Scholar 

  66. Moreau, R. et al. A randomized trial of 6-month norfloxacin therapy in patients with Child-Pugh class C cirrhosis. J. Hepatol. 66 (Suppl. 1), S1 (2017).

    Google Scholar 

  67. Campillo, B., Dupeyron, C., Richardet, J. P., Mangeney, N. & Leluan, G. Epidemiology of severe hospital-acquired infections in patients with liver cirrhosis: effect of long-term administration of norfloxacin. Clin. Infect. Dis. 26, 1066–1070 (1998).

    PubMed  CAS  Google Scholar 

  68. Fernández, J. et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 55, 1551–1561 (2012).

    PubMed  Google Scholar 

  69. Adachi, J. A. & Dupont, H. L. Rifaximin: a novel nonabsorbed rifamycin for gastrointestinal disorders. Clin. Infect. Dis. 42, 541–547 (2006).

    PubMed  CAS  Google Scholar 

  70. Reigadas, E. et al. Rifaximin-resistant Clostridium difficile strains isolated from symptomatic patients. Anaerobe 48, 269–272 (2017).

    PubMed  CAS  Google Scholar 

  71. Jiang, Z. D., Ke, S. & Dupont, H. L. Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei. Int. J. Antimicrob. Agents 35, 278–281 (2010).

    PubMed  CAS  Google Scholar 

  72. Brown, E. L., Xue, Q., Jiang, Z. D., Xu, Y. & Dupont, H. L. Pretreatment of epithelial cells with rifaximin alters bacterial attachment and internalization profiles. Antimicrob. Agents Chemother. 54, 388–396 (2010).

    PubMed  CAS  Google Scholar 

  73. Bajaj, J. S. et al. Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy. PLOS ONE 8, e60042 (2013).

    PubMed  PubMed Central  CAS  Google Scholar 

  74. Fiorucci, S. et al. Inhibition of intestinal bacterial translocation with rifaximin modulates lamina propria monocytic cells reactivity and protects against inflammation in a rodent model of colitis. Digestion 66, 246–256 (2002).

    PubMed  CAS  Google Scholar 

  75. Kalambokis, G. N. et al. Rifaximin improves systemic hemodynamics and renal function in patients with alcohol-related cirrhosis and ascites. Clin. Gastroenterol. Hepatol. 10, 815–818 (2012).

    PubMed  CAS  Google Scholar 

  76. Kimer, N. et al. Rifaximin has no effect on hemodynamics in decompensated cirrhosis: A randomized, double-blind, placebo-controlled trial. Hepatology 65, 592–603 (2017).

    PubMed  CAS  Google Scholar 

  77. Qin, N. et al. Alterations of the human gut microbiome in liver cirrhosis. Nature 513, 59–64 (2014).

    PubMed  CAS  Google Scholar 

  78. Bass, N. M. et al. Rifaximin treatment in hepatic encephalopathy. N. Engl. J. Med. 362, 1071–1081 (2010).

    PubMed  CAS  Google Scholar 

  79. Hanouneh, M. A. et al. The role of rifaximin in the primary prophylaxis of spontaneous bacterial peritonitis in patients with liver cirrhosis. J. Clin. Gastroenterol. 46, 709–715 (2012).

    PubMed  CAS  Google Scholar 

  80. Vlachogiannakos, J. et al. Long-term administration of rifaximin improves the prognosis of patients with decompensated alcoholic cirrhosis. J. Gastroenterol. Hepatol. 28, 450–455 (2013).

    PubMed  CAS  Google Scholar 

  81. Dong, T., Aronsohn, A., Gautham Reddy, K. & Te, H. S. Rifaximin decreases the incidence and severity of acute kidney injury and hepatorenal syndrome in cirrhosis. Dig. Dis. Sci. 61, 3621–3626 (2016).

    PubMed  CAS  Google Scholar 

  82. Lutz, P. et al. Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascites. PLOS ONE 9, e93909 (2014).

    PubMed  PubMed Central  Google Scholar 

  83. Hanafy, A. S. & Hassaneen, A. M. Rifaximin and midodrine improve clinical outcome in refractory ascites including renal function, weight loss, and short-term survival. Eur. J. Gastroenterol. Hepatol. 28, 1455–1461 (2016).

    PubMed  CAS  Google Scholar 

  84. Bajaj, J. S. et al. Oral rifaximin soluble solid dispersion immediate-release 40 mg prevents development of cirrhosis-related complications: a phase 2, randomized, multicenter, double-blind, placebo-controlled trial. Hepatology 64 (Suppl. 1), 1027A (2016).

    Google Scholar 

  85. Kamal, F. et al. Rifaximin for the prevention of spontaneous bacterial peritonitis and hepatorenal syndrome in cirrhosis: a systematic review and meta-analysis. Eur. J. Gastroenterol. Hepatol. 29, 1109–1117 (2017).

    PubMed  CAS  Google Scholar 

  86. Gómez-Hurtado, I. et al. Norfloxacin is more effective than rifaximin in avoiding bacterial translocation in an animal model of cirrhosis. Liver Int. 38, 295–302 (2018).

    PubMed  Google Scholar 

  87. Kimer, N. et al. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: a randomized trial. J. Gastroenterol. Hepatol. 33, 307–314 (2018).

    PubMed  CAS  Google Scholar 

  88. Villa, E. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology 143, 1253–1260 (2012).

    CAS  PubMed  Google Scholar 

  89. Cerini, F. et al. Enoxaparin reduces hepatic vascular resistance and portal pressure in cirrhotic rats. J. Hepatol. 64, 834–842 (2016).

    PubMed  CAS  Google Scholar 

  90. Fortea, J. I. et al. Enoxaparin does not ameliorate liver fibrosis or portal hypertension in rats with advanced cirrhosis. Liver Int. 38, 102–112 (2018).

    PubMed  CAS  Google Scholar 

  91. Copple, B. L. & Li, T. Pharmacology of bile acid receptors: evolution of bile acids from simple detergents to complex signaling molecules. Pharmacol. Res. 104, 9–21 (2016).

    PubMed  CAS  Google Scholar 

  92. Distrutti, E. et al. Bile acid activated receptors are targets for regulation of integrity of gastrointestinal mucosa. J. Gastroenterol. 50, 707–719 (2015).

    PubMed  CAS  Google Scholar 

  93. Verbeke, L. et al. The FXR agonist obeticholic acid prevents gut barrier dysfunction and bacterial translocation in cholestatic rats. Am. J. Pathol. 185, 409–419 (2015).

    PubMed  CAS  Google Scholar 

  94. Ubeda, M. et al. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. J. Hepatol. 64, 1049–1057 (2016).

    PubMed  CAS  Google Scholar 

  95. Lutz, P. et al. A farnesoid X receptor polymorphism predisposes to spontaneous bacterial peritonitis. Dig. Liver Dis. 46, 1047–1050 (2014).

    PubMed  CAS  Google Scholar 

  96. Verbeke, L. et al. Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats. Hepatology 59, 2286–2298 (2014).

    PubMed  CAS  Google Scholar 

  97. Nevens, F. et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N. Engl. J. Med. 375, 631–643 (2016).

    PubMed  CAS  Google Scholar 

  98. Bajaj, J. S. et al. Altered profile of human gut microbiome is associated with cirrhosis and its complications. J. Hepatol. 60, 940–947 (2014).

    PubMed  CAS  Google Scholar 

  99. Fukui, H. Gut microbiome-based therapeutics in liver cirrhosis: basic consideration for the next step. J. Clin. Transl Hepatol. 5, 249–260 (2017).

    PubMed  PubMed Central  Google Scholar 

  100. Wiest, R. Albillos, A., Trauner, M., Bajaj, J. S. & Jalan, R. Targeting the gut-liver axis in liver disease. J. Hepatol. 67, 1084–1103 (2017).

    PubMed  CAS  Google Scholar 

  101. Saab, S. et al. Probiotics are helpful in hepatic encephalopathy: a meta-analysis of randomized trials. Liver Int. 36, 986–993 (2016).

    PubMed  CAS  Google Scholar 

  102. Viramontes Hörner, D., Avery, A. & Stow, R. The effects of probiotics and symbiotics on risk factors for hepatic encephalopathy: a systematic review. J. Clin. Gastroenterol. 51, 312–323 (2017).

    PubMed  Google Scholar 

  103. Woodhouse, C. A., Patel, V. C., Singanayagam, A. & Shawcross, D. L. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment. Pharmacol. Ther. 47, 192–202 (2017).

    PubMed  Google Scholar 

  104. Tousoulis, D. et al. Innate and adaptive inflammation as a therapeutic target in vascular disease: the emerging role of statins. J. Am. Coll. Cardiol. 63, 2491–2502 (2014).

    PubMed  CAS  Google Scholar 

  105. Trebicka, J. et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. Hepatology 46, 242–253 (2007).

    PubMed  CAS  Google Scholar 

  106. Abraldes, J. G. et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology 136, 1651–1658 (2009).

    PubMed  CAS  Google Scholar 

  107. Pollo-Flores, P. et al. Three months of simvastatin therapy vs. placebo for severe portal hypertension in cirrhosis: a randomized controlled trial. Dig. Liver. Dis. 47, 957–963 (2015).

    PubMed  CAS  Google Scholar 

  108. Zafra, C. et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 126, 749–755 (2004).

    PubMed  CAS  Google Scholar 

  109. Abraldes, J. G. et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology 150, 1160–1170 (2016).

    PubMed  CAS  Google Scholar 

  110. Yang, Y. H. et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J. Hepatol. 63, 1111–1117 (2015).

    PubMed  CAS  Google Scholar 

  111. Huang, Y. W. et al. Statins Reduce the risk of cirrhosis and its decompensation in chronic hepatitis B patients: a nationwide cohort study. Am. J. Gastroenterol. 111, 976–985 (2016).

    PubMed  CAS  Google Scholar 

  112. Simon, T. G., Bonilla, H., Yan, P., Chung, R. T. & Butt, A. A. Atorvastatin and fluvastatin are associated with dose-dependent reductions in cirrhosis and hepatocellular carcinoma, among patients with hepatitis C virus: results from ERCHIVES. Hepatology 64, 47–57 (2016).

    PubMed  CAS  Google Scholar 

  113. Mohanty, A., Tate, J. P. & Garcia-Tsao, G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology 150, 430–440 (2016).

    PubMed  CAS  Google Scholar 

  114. Bang, U. C., Benfield, T. & Bendtsen, F. Reduced risk of decompensation and death associated with use of statins in patients with alcoholic cirrhosis. A nationwide case-cohort study. Aliment. Pharmacol. Ther. 46, 673–680 (2017).

    PubMed  CAS  Google Scholar 

  115. Chang, F. M. et al. Statins decrease the risk of decompensation in hepatitis B virus- and hepatitis C virus-related cirrhosis: a population-based study. Hepatology 66, 896–907 (2017).

    PubMed  CAS  Google Scholar 

  116. Weersink, R. A., Drenth, J. P. & Borgsteede, S. D. Altered pharmacokinetics of statins explain increased risk of rhabdomyolysis in advanced cirrhosis. Gastroenterology 151, 1036 (2016).

    PubMed  Google Scholar 

  117. Rodríguez, S. et al. A nitric oxide-donating statin decreases portal pressure with a better toxicity profile than conventional statins in cirrhotic rats. Sci. Rep. 7, 40461 (2017).

    PubMed  PubMed Central  Google Scholar 

  118. Sort, P. et al. Effect of intravenous albumin on renal impairment and mortality in patients with cirrhosis and spontaneous bacterial peritonitis. N. Engl. J. Med. 341, 403–409 (1999).

    PubMed  CAS  Google Scholar 

  119. Bernardi, M., Caraceni, P., Navickis, R. J. & Wilkes, M. M. Albumin infusion in patients undergoing large-volume paracentesis: a meta-analysis of randomized trials. Hepatology 55, 1172–1181 (2012).

    PubMed  CAS  Google Scholar 

  120. Ortega, R. et al. Terlipressin therapy with and without albumin for patients with hepatorenal syndrome: results of a prospective, nonrandomized study. Hepatology 36, 941–948 (2002).

    PubMed  CAS  Google Scholar 

  121. Garcia-Martinez, R. et al. Albumin: pathophysiologic basis of its role in the treatment of cirrhosis and its complications. Hepatology 58, 1836–1846 (2013).

    PubMed  CAS  Google Scholar 

  122. Bernardi, M., Ricci, C. S. & Zaccherini, G. Role of human albumin in the management of complications of liver cirrhosis. J. Clin. Exp. Hepatol. 4, 302–311 (2014).

    PubMed  PubMed Central  Google Scholar 

  123. Oettl, K. et al. Oxidative albumin damage in chronic liver failure: relation to albumin binding capacity, liver dysfunction and survival. J. Hepatol. 59, 978–983 (2013).

    PubMed  CAS  Google Scholar 

  124. Domenicali, M. et al. Posttranscriptional changes of serum albumin: clinical and prognostic significance in hospitalized patients with cirrhosis. Hepatology 60, 1851–1860 (2014).

    PubMed  CAS  Google Scholar 

  125. Giannone, F. A. et al. Ischaemia-modified albumin: a marker of bacterial infection in hospitalized patients with cirrhosis. Liver Int. 35, 2425–2432 (2015).

    PubMed  CAS  Google Scholar 

  126. Baldassarre, M. et al. Albumin homodimers in patients with cirrhosis: clinical and prognostic relevance of a novel identified structural alteration of the molecule. Sci. Rep. 6, 35987 (2016).

    PubMed  PubMed Central  CAS  Google Scholar 

  127. Bortoluzzi, A. et al. Positive cardiac inotropic effect of albumin infusion in rodents with cirrhosis and ascites: molecular mechanisms. Hepatology 57, 266–276 (2013).

    PubMed  CAS  Google Scholar 

  128. Fernández, J. et al. A randomized unblinded pilot study comparing albumin vs. hydroxyethyl starch in spontaneous bacterial peritonitis. Hepatology 42, 627–634 (2005).

    PubMed  Google Scholar 

  129. O’Brien, A. J. et al. Immunosuppression in acutely decompensated cirrhosis is mediated by prostaglandin E2. Nat. Med. 20, 518–523 (2014).

    PubMed  PubMed Central  Google Scholar 

  130. Gentilini, P. et al. Albumin improves the response to diuretics in patients with cirrhosis and ascites: results of a randomized, controlled trial. J. Hepatol. 30, 639–645 (1999).

    PubMed  CAS  Google Scholar 

  131. Romanelli, R. G. et al. Long-term albumin infusion improves survival in patients with cirrhosis and ascites: an unblinded randomized trial. World. J. Gastroenterol. 12, 1403–1407 (2006).

    PubMed  PubMed Central  CAS  Google Scholar 

  132. Caraceni, P. et al. Long-term albumin administration in decompensated cirrhosis: an open label randomized trial. Lancet 391, 2417–2429 (2018).

    PubMed  CAS  Google Scholar 

  133. Solà, E. et al. Midodrine and albumin for prevention of complications of cirrhosis in patients in the waiting list for liver transplantation. A randomized, multicenter, double-blind, placebo-controlled trial. J. Hepatol. 66 (Suppl. 1), S11 (2017).

    Google Scholar 

  134. Kedarisetty, C. K. et al. Combination of granulocyte colony-stimulating factor and erythropoietin improves outcomes of patients with decompensated cirrhosis. Gastroenterology 148, 1362–1370 (2015).

    PubMed  CAS  Google Scholar 

  135. Verma, N. et al. Outcomes after multiple courses of granulocyte-colony stimulating factor and growth hormone in decompensated cirrhosis: randomized trial. Hepatology. https://doi.org/10.1002/hep.29763 (2017).

    Article  Google Scholar 

  136. Suk, K. T. et al. Transplantation with autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: phase 2 trial. Hepatology 64, 2185–2197 (2016).

    PubMed  CAS  Google Scholar 

  137. Newsome, P. N. et al. Granulocyte colony-stimulating factor and autologous CD133-positive stem-cell therapy in liver cirrhosis (REALISTIC): an open-label, randomised, controlled phase 2 trial. Lancet Gastroenterol. Hepatol. 3, 25–36 (2018).

    PubMed  Google Scholar 

  138. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03202498 (2018).

  139. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT03150459 (2018).

  140. Kalafately, M. et al. Malnutrition and sarcopenia predict post-liver transplantation outcomes independently of the Model for End-stage Liver Disease score. J. Cachexia Sarcopenia Muscle 8, 113–121 (2017).

    Google Scholar 

  141. Montano-Loza, A. et al. Muscle wasting is associated with mortality in patients with cirrhosis. Clin. Gastroenterol. Hepatol. 10, 166–173 (2012).

    PubMed  Google Scholar 

  142. Lai, J. C. et al. Development of a novel frailty index to predict mortality in patients with end-stage liver disease. Hepatology 66, 564–574 (2017).

    PubMed  Google Scholar 

Download references

Acknowledgements

The authors thank M. Baldassare for figure editing and A. P. Collins for editing the manuscript.

Reviewer information

Nature Reviews Gastroenterology and Hepatology thanks J. Abraldes, M. Peck-Radosavljevic and the other anonymous reviewer(s) for their contribution to the peer review of this work.

Author information

Authors and Affiliations

  1. Department of Medical and Surgical Sciences, Alma Mater Studiorum – University of Bologna, Bologna, Italy

    Mauro Bernardi & Paolo Caraceni

Authors
  1. Mauro Bernardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paolo Caraceni
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

The authors contributed equally to all the aspects of this article.

Corresponding author

Correspondence to Mauro Bernardi.

Ethics declarations

Competing interests

M.B. has been a scientific consultant for Baxalta, CSL Behring and Grifols and speaker for AbbVie Italia, Baxalta, CSL Behring, Gilead Science, Grifols and Octapharma. P.C. has been a speaker for Baxalta, Grifols, Kedrion and Octapharma. He also participates in advisory boards for Grifols and has been a scientific consultant for Kedrion. He is also the recipient of a research grant from Octapharma.

Additional information

Publisher’s note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Related links

Protein Data Bank: http://www.rcsb.org/pdb/home/home.do

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Bernardi, M., Caraceni, P. Novel perspectives in the management of decompensated cirrhosis. Nat Rev Gastroenterol Hepatol 15, 753–764 (2018). https://doi.org/10.1038/s41575-018-0045-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41575-018-0045-2

This article is cited by

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing